What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary areas of study are Internal medicine, Immunology, Immunotherapy, Colorectal cancer and Oncology.
His Internal medicine study combines topics in areas such as Gastroenterology and Surgery.
He has researched Immunotherapy in several fields, including Cytotoxic T cell and Dendritic cell, Antigen.
His study on Oxaliplatin is often connected to In patient as part of broader study in Colorectal cancer.
His Oncology research is multidisciplinary, incorporating elements of Cohort and Adenocarcinoma.
While the research belongs to areas of Immune system, Michael A. Morse spends his time largely on the problem of In vivo, intersecting his research to questions surrounding Cellular immunity.
His most cited work include:
- The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells (2225 citations)
- The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells (2225 citations)
- Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer (1319 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Oncology, Immunology, Immune system and Immunotherapy are his primary areas of study.
The Internal medicine study combines topics in areas such as Gastroenterology and Surgery.
His work on Renal cell carcinoma as part of general Oncology study is frequently linked to In patient, therefore connecting diverse disciplines of science.
In his study, Clinical trial and Antibody is strongly linked to Cancer, which falls under the umbrella field of Immunology.
Michael A. Morse works mostly in the field of Immune system, limiting it down to concerns involving Cancer research and, occasionally, Breast cancer.
The various areas that he examines in his Immunotherapy study include Carcinoembryonic antigen and Melanoma.
He most often published in these fields:
- Internal medicine (39.93%)
- Oncology (30.12%)
- Immunology (27.99%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (39.93%)
- Oncology (30.12%)
- Cancer research (18.00%)
In recent papers he was focusing on the following fields of study:
Michael A. Morse mainly focuses on Internal medicine, Oncology, Cancer research, Cancer and Immunotherapy.
In the field of Internal medicine, his study on Colorectal cancer, Adverse effect and Chemotherapy overlaps with subjects such as In patient.
His work carried out in the field of Oncology brings together such families of science as Tolerability, Irinotecan, Oxaliplatin, Clinical endpoint and Nivolumab.
His Cancer research research incorporates elements of Immune checkpoint, T cell, Metastasis, Breast cancer and Antitumor activity.
His Cancer study integrates concerns from other disciplines, such as Melanoma and Immune system.
His Immunotherapy study is concerned with the larger field of Immunology.
Between 2016 and 2021, his most popular works were:
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study (897 citations)
- Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer (608 citations)
- Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. (93 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Michael A. Morse mainly investigates Internal medicine, Oncology, Nivolumab, Immunotherapy and Colorectal cancer.
Michael A. Morse regularly ties together related areas like Gastroenterology in his Internal medicine studies.
His Oncology research is multidisciplinary, incorporating perspectives in Cancer, Tyrosine-kinase inhibitor, Concomitant, Surgery and Prior Therapy.
His research in Nivolumab intersects with topics in Ipilimumab and Carcinoma.
His study with Immunotherapy involves better knowledge in Immunology.
His work on DNA mismatch repair, Irinotecan and Oxaliplatin as part of general Colorectal cancer research is frequently linked to Microsatellite instability, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
